Current innovations in graft-versus-host disease (GvHD) prophylaxis include T cell depletion and administering anti-thymocyte globulin (ATG) based on lymphocyte count pre-conditioning regimen. Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the production of prolymphocytes from CD34 stem cells to prevent GvHD. Preclinical studies have demonstrated reduced rates of GvHD in patients receiving prolymphocytes. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.